There are doubts about the efficiency of Lianhua Qingwen for COVID-19. The clinical trails are not persuasive. Yiling's performance is not sustainable after COVID. So, investors should remain cautious
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.